Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

ADA: Empagliflozin overcomes FDA concerns

Boehringer and Lilly expect decision on diabetes treatment by end of 2014

- PMLiVE

Counting value under the US Sunshine Act

International in scope, the implication of the transparency legislation are anything but clear

- PMLiVE

Fishawack appoints John Handley as new chairman

He joins to support UK group's acquisition plans

- PMLiVE

Designing unique patient solutions in rare disease

Living with any chronic health condition can be demanding, but rare diseases bring a unique set of challenges for patients.

As Apple’s HealthKit is to iOS so could Google Fit be to Android?

Google said to be readying health data service of its own

- PMLiVE

Michael Le Brocq joins Langland

Takes up role as business unit director

- PMLiVE

Omontys terminal as Takeda switches off support

Japanese company ends anaemia treatment partnership with Affymax

- PMLiVE

Sanofi and Medtronic to develop drug-device combos in diabetes

Companies tell PMLiVE their new alliance will take an ‘open innovation’ approach

- PMLiVE

ADA: AZ plans to file Onglyza/Forxiga pill by year-end

Diabetes prospects could help justify decision to turn down Pfizer bid

- PMLiVE

Breathing new life into pharma’s innovation engine

The rise of new collaborative approaches to R&D

- PMLiVE

ADA: Lilly/Boehringer insulin glargine matches Lantus

Biosimilar demonstrates equal efficacy to Sanofi’s big-selling diabetes treatment

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links